PubHawk
April 2015 PMID 25457756

FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity.

Joshua Lehrer-Graiwer, Parmanand Singh, Amr Abdelbaky, Esad Vucic, Magnus Korsgren, Amos Baruch, Jill Fredrickson, Nick van Bruggen, Meina T Tang, Bjorn Frendeus, James H F Rudd, Frank Hsieh, Christie M Ballantyne, Brian Ghoshhajra, Robert S Rosenson

Download social card

Mentions

4
Peak: 2 in Jul 2022
across 2 sources since Jul 2022

Extended reach

989,172
potential audience

Total likes

18,916

Video views

988,923

Mentions per month

Jul 2022 – Apr 2023

Where it's discussed

  • X / Twitter2 posts
  • YouTube2 videos

AI synopsis

What people are saying

The discussions reflect a moderate level of interest and cautious agreement, as seen in comments about the potential significance of OxLDL and LpPLA2 as markers. The tone is analytical but somewhat reserved, emphasizing the uncertainty of therapeutic effects and the implications of a slight rise in OxLDL levels, indicating recognition of the study's relevance but limited deep engagement or perceived impact.

AgreementModerate agreement

Post(s) acknowledge the importance of oxidized LDL and related markers but express uncertainty about therapeutic effects, indicating a cautious agreement.

InterestModerate interest

Discussions show moderate interest, focusing on the potential significance of biomarkers without deep engagement with the study's detailed findings.

EngagementNeutral engagement

Comments are somewhat surface-level, raising questions rather than analyzing data or discussing broader implications extensively.

ImpactNeutral impact

The posts suggest some recognition of the research's importance but do not demonstrate a significant influence on clinical practice or scientific discourse.

Abstract in brief

  • This study investigates the use of FDG-PET imaging to detect oxidized LDL in patients with stable atherosclerotic disease, aiming to better understand inflammation in blood vessels.
  • It is a phase II clinical trial focusing on the safety and tolerability of a treatment, as well as its potential to reduce inflammation related to atherosclerosis.
  • The research explores whether targeting oxidized LDL can help manage or monitor the progression of atherosclerotic disease through advanced imaging techniques.]
Read the full abstract

Top posts

Most liked on X and Bluesky
fipco
@fipco · X

2nd, OxLDL & LpPLA2 may be important markers. To date, medicines targeting those pathways haven’t panned out. Unclear what effect a 5% rise in OxLDL has. https://t.co/GqnM4w2DZt https://t.co/1GK8oJu7BE /3

Jul 2, 2022 · 6 likes · 2 shares · 234 followers View post →
Rick Fromknecht
@Sabre2870 · X

RT @fipco: 2nd, OxLDL & LpPLA2 may be important markers. To date, medicines targeting those pathways haven’t panned out. Unclear what effec…

Jul 26, 2022 · 2 shares · 7 followers View post →

All mentions

Rick Fromknecht
@Sabre2870 · X

RT @fipco: 2nd, OxLDL & LpPLA2 may be important markers. To date, medicines targeting those pathways haven’t panned out. Unclear what effec…

Jul 26, 2022 · 2 shares · 7 followers View post →
fipco
@fipco · X

2nd, OxLDL & LpPLA2 may be important markers. To date, medicines targeting those pathways haven’t panned out. Unclear what effect a 5% rise in OxLDL has. https://t.co/GqnM4w2DZt https://t.co/1GK8oJu7BE /3

Jul 2, 2022 · 6 likes · 2 shares · 234 followers View post →